Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | REN | P00797 | 13/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660648 | 0.83 | REN (0.55) | SLC6A4RENCYP3A4 | |
| SCHEMBL661932 | 0.79 | REN (0.55) | SLC6A4RENSLC6A2CYP3A4KCNH2 | |
| SCHEMBL663699 | 0.74 | REN (0.77) | RENCYP3A4 | |
| SCHEMBL662936 | 0.68 | REN (0.54) | SLC6A4RENSLC6A2CYP3A4KCNH2 | |
| SCHEMBL8171105 | 0.66 | SLC6A4 (0.59) | SLC6A4RENSLC6A2CYP3A4KCNH2 | |
| SCHEMBL5072308 | 0.64 | SLC6A4 (0.76) | SLC6A4RENSLC6A2CYP3A4KCNH2 | |
| SCHEMBL5072329 | 0.64 | SLC6A4 (0.59) | SLC6A4RENSLC6A2CYP3A4KCNH2 | |
| SCHEMBL662533 | 0.64 | SLC6A4 (0.53) | SLC6A4RENSLC6A2CYP3A4KCNH2 | |
| SCHEMBL3972684 | 0.63 | CCR5 (0.35) | REN | |
| SCHEMBL663164 | 0.60 | REN (1.00) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | SLC6A4 1352/4885REN 1/4885SLC6A2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.